What is Evozyne?
Evozyne operates at the vanguard of computational biology, specializing in the design of novel therapeutic proteins. By utilizing its proprietary AI-native platform, EvoGen, the company optimizes protein sequences to enhance potency, stability, and specificity, specifically targeting complex immune-mediated diseases. This approach addresses a significant gap in the current pharmaceutical market, where many patients remain underserved by traditional therapeutic modalities.
The company's operational model is anchored by EvoLab, a high-throughput facility that bridges the gap between digital design and physical validation. By synthesizing and testing thousands of protein candidates, Evozyne generates a robust, proprietary dataset that informs its immunology pipeline. This data-centric methodology allows the firm to iterate rapidly, moving beyond the limitations of conventional drug discovery and positioning itself as a leader in the development of scalable, precision-engineered immune therapies.
How much funding has Evozyne raised?
Evozyne has raised a total of $81M across 1 funding round:
Series B
$81M
Series B (2023): $81M with participation from OrbiMed, NVIDIA, Valor Equity Partners, Fidelity, and Paragon Biosciences
Key Investors in Evozyne
OrbiMed
OrbiMed Advisors LLC is a specialized investment firm focused on the healthcare sector, managing capital across biopharmaceuticals, medical devices, and digital health platforms.
NVIDIA
NVIDIA is a global leader in artificial intelligence computing, providing the advanced hardware and software infrastructure necessary for high-performance machine learning applications.
Valor Equity Partners
Valor Equity Partners is a Chicago-based investment firm that provides strategic financial services and operational support to high-growth businesses.
What's next for Evozyne?
Looking ahead, the strategic deployment of this capital will likely focus on the expansion of the Evozyne immunology pipeline and the further refinement of the EvoGen platform. As the company transitions from a development-focused entity to a more mature clinical-stage organization, the focus will shift toward validating its lead candidates in human trials. The backing from high-profile investors suggests a long-term commitment to building a sustainable, data-driven pharmaceutical powerhouse capable of addressing unmet medical needs on a global scale.
Furthermore, the company is expected to leverage its existing partnerships and infrastructure to accelerate the transition of its protein designs into viable clinical assets. By maintaining its focus on high-throughput synthesis and AI-driven optimization, Evozyne is poised to remain a key player in the evolving landscape of generative biology, potentially setting new standards for how therapeutic proteins are discovered and brought to market.
